Welcome to the Starpharma Investor CentreStarpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform. |
 |
Latest News & Announcements
Quarterly Activities Report & Appendix 4C (ASX Announcement)
Apr 28th, 2023
Starpharma (ASX: SPL, OTCQX: SPHRY) today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 March 2023 (Q3 FY23). Starpharma’s net operating cash outflows for the quarter were $4.9 million, and the closing cash balance as at 31 March 2023 was $38.9 million.
Read More
HER2-targeted DEP® SN-38 ADC outperforms in HER2+ human cancer model (ASX Announcement)
Apr 26th, 2023
Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it has developed a HER2-targeted DEP® SN-38 antibody-drug conjugate (ADC), which has shown significant anti-tumour activity in a HER2+ human ovarian cancer xenograft model, outperforming the approved ADC product, Enhertu®[1].
Read More
Reports & Presentations
Click here for financial reports archive
Quarterly Activities Report & Appendix 4C (ASX Announcement)
Apr 28th, 2023
Starpharma (ASX: SPL, OTCQX: SPHRY) today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 March 2023 (Q3 FY23). Starpharma’s net operating cash outflows for the quarter were $4.9 million, and the closing cash balance as at 31 March 2023 was $38.9 million.
Read More
HER2-targeted DEP® SN-38 ADC outperforms in HER2+ human cancer model (ASX Announcement)
Apr 26th, 2023
Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it has developed a HER2-targeted DEP® SN-38 antibody-drug conjugate (ADC), which has shown significant anti-tumour activity in a HER2+ human ovarian cancer xenograft model, outperforming the approved ADC product, Enhertu®[1].
Read More